-+ 0.00%
-+ 0.00%
-+ 0.00%

MeiraGTx posts corporate deck highlighting late-stage gene therapy pipeline, riboswitch platform

PUBT·08/13/2026 12:23:56
Listen to the news
MeiraGTx posts corporate deck highlighting late-stage gene therapy pipeline, riboswitch platform
  • MeiraGTx highlighted four late-stage gene therapy programs, led by AAV-AQP1 in pivotal Phase 2 for radiation-induced xerostomia.
  • BLA filing for AAV-AQP1 targeted for mid 2027, supported by Breakthrough Therapy, RMAT, orphan drug designations.
  • Botaretigene sparoparvovec in X-linked retinitis pigmentosa completed Phase 3; BLA and MAA submissions planned in 2026.
  • AAV-GAD in Parkinson’s disease described as Phase 3 ready; potential BLA filing targeted in 2028.
  • Partnership updates included Eli Lilly paying USD 75 million upfront for AAV-AIPL1, with up to USD 135 million near-term milestones.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeiraGTx Holdings plc published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.